Haleon is teaming up with the University of Sydney to launch a five-year fellowship to research the efficacy of dietary supplements for ...
Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...
Futura Medical, the consumer healthcare company behind Eroxon, announced on Monday that a $5m milestone payment had been ...
Goldman Sachs raises AstraZeneca price target to 16,046 (15,914) pence - 'buy' Barclays raises Standard Chartered price target to 890 (850) pence - 'equal weight' Barclays raises Harbour Energy price ...
Pfizer sold 640 million shares in Haleon for 380p each, reducing its holding in the consumer healthcare firm by 7.6% ...
Separately, Haleon will also buy around £230 million worth of its shares from Pfizer at the price set in the share offering, ...
Pfizer is in value territory, trading at just 10.74X forward earnings with a 5.88% annual dividend yield and over $10 billion in cash after selling $2.4 billion of its HLN position.
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...
Haleon plc (LSE/NYSE: HLN), a global consumer health company, disclosed today that Alan Stewart has resigned from its board of directors. Stewart's departure was effective as of Sunday ...
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
US pharmaceutical giant Pfizer concluded its second sell-down in its consumer healthcare spin-off, Haleon. It raised £2.432bn ...
Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback